{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:37:14Z","timestamp":1789000634295,"version":"build-2803163510"},"reference-count":57,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Antiobesity pharmacotherapy is recommended for adolescents ages 12 years and older with obesity. Several medications have been approved by the US Food and Drug Administration for adolescent use, but the most cost-effective medication remains unclear.<\/jats:p><\/jats:sec>Objective<\/jats:title>To estimate the cost-effectiveness of lifestyle counseling alone and as adjunct to liraglutide, mid-dose phentermine and topiramate (7.5 mg phentermine and 46 mg topiramate), top-dose phentermine and topiramate (15 mg phentermine and 92 mg topiramate), or semaglutide among adolescent patients with obesity.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This economic evaluation used a microsimulation model to project health and cost outcomes of lifestyle counseling alone and adjunct to liraglutide, mid-dose phentermine and topiramate, top-dose phentermine and topiramate, or semaglutide over 13 months, 2 years, and 5 years among a hypothetical cohort of 100\u202f000 adolescents with obesity, defined as an initial body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of 37. Model inputs were derived from clinical trials, published literature, and national sources. Data were analyzed from April 2022 to July 2023.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Lifestyle counseling alone and as adjunct to liraglutide, mid-dose phentermine and topiramate, top-dose phentermine and topiramate, or semaglutide.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The main outcome was quality-adjusted life years (QALYs), costs (2022 US dollars), and incremental cost-effectiveness ratios (ICERs), with future costs and QALYs discounted 3.0% annually. A strategy was considered cost-effective if the ICER was less than $100\u202f000 per QALY gained. The preferred strategy was determined as the strategy with the greatest increase in QALYs while being cost-effective. One-way and probabilistic sensitivity analyses were used to assess parameter uncertainty.<\/jats:p><\/jats:sec>Results<\/jats:title>The model simulated 100\u202f000 adolescents at age 15 with an initial BMI of 37, of whom 58\u202f000 (58%) were female. At 13 months and 2 years, lifestyle counseling was estimated to be the preferred strategy. At 5 years, top-dose phentermine and topiramate was projected to be the preferred strategy with an ICER of $56\u202f876 per QALY gained vs lifestyle counseling. Semaglutide was projected to yield the most QALYs, but with an unfavorable ICER of $1.1 million per QALY gained compared with top-dose phentermine and topiramate. Model results were most sensitive to utility of weight reduction and weight loss of lifestyle counseling and top-dose phentermine and topiramate.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this economic evaluation of pharmacotherapy for adolescents with obesity, top-dose phentermine and topiramate as adjunct to lifestyle counseling was estimated to be cost-effective after 5 years. Long-term clinical trials in adolescents are needed to fully evaluate the outcomes of pharmacotherapy, especially into adulthood.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.29178","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T15:57:55Z","timestamp":1693497475000},"page":"e2329178","source":"Crossref","is-referenced-by-count":42,"title":["Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents"],"prefix":"10.1001","volume":"6","author":[{"given":"Francesca","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon K.","family":"Bellows","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Xinhui","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center, New York, New York"},{"name":"Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Aziz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Woo Baidal","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin","family":"Hur","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"issue":"25","key":"zoi230843r1","first-page":"1","article-title":"Changes in terminology for childhood overweight and obesity.","author":"Ogden","year":"2010","journal-title":"Natl Health Stat Report"},{"issue":"2","key":"zoi230843r2","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/oby.2019.27.issue-2","article-title":"Clinical considerations regarding the use of obesity pharmacotherapy in adolescents with obesity.","volume":"27","author":"Srivastava","year":"2019","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"zoi230843r3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/oby.2019.27.issue-1","article-title":"Obesity as a disease: the Obesity Society 2018 position statement.","volume":"27","author":"Jastreboff","year":"2019","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"zoi230843r4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S2213-8587(22)00047-X","article-title":"Obesity in children and adolescents: epidemiology, causes, assessment, and management.","volume":"10","author":"Jebeile","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"25","key":"zoi230843r5","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1056\/NEJMoa1503840","article-title":"Body-mass index in 2.3 million adolescents and cardiovascular death in adulthood.","volume":"374","author":"Twig","year":"2016","journal-title":"N Engl J Med"},{"issue":"288","key":"zoi230843r6","first-page":"1","article-title":"Prevalence of obesity among adults and youth: United States, 2015-2016.","author":"Hales","year":"2017","journal-title":"NCHS Data Brief"},{"issue":"2","key":"zoi230843r7","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-060640","article-title":"Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity.","volume":"151","author":"Hampl","year":"2023","journal-title":"Pediatrics"},{"issue":"17","key":"zoi230843r8","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1001\/jama.2019.14725","article-title":"Treatment of adolescent obesity in 2020.","volume":"322","author":"Cardel","year":"2019","journal-title":"JAMA"},{"issue":"12","key":"zoi230843r9","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1001\/2013.jamapediatrics.319","article-title":"Response of severely obese children and adolescents to behavioral treatment.","volume":"166","author":"Danielsson","year":"2012","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"23","key":"zoi230843r10","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1001\/jama.2017.6803","article-title":"Screening for obesity in children and adolescents: US Preventive Services Task Force recommendation statement.","volume":"317","author":"Grossman","year":"2017","journal-title":"JAMA"},{"issue":"15","key":"zoi230843r11","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1161\/CIR.0b013e3182a5cfb3","article-title":"Severe obesity in children and adolescents: identification, associated health risks, and treatment approaches: a scientific statement from the American Heart Association.","volume":"128","author":"Kelly","year":"2013","journal-title":"Circulation"},{"issue":"22","key":"zoi230843r12","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity.","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"key":"zoi230843r13","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200014","article-title":"Phentermine\/topiramate for the treatment of adolescent obesity.","author":"Kelly","year":"2022.","journal-title":"NEJM Evid"},{"issue":"24","key":"zoi230843r14","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity.","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"key":"zoi230843r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.04.004","article-title":"Developing criteria for health economic quality evaluation tool.","author":"Kim","year":"2023","journal-title":"Value Health"},{"issue":"2","key":"zoi230843r16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/osp4.v6.2","article-title":"The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity.","volume":"6","author":"Lee","year":"2019","journal-title":"Obes Sci Pract"},{"issue":"2","key":"zoi230843r17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1177\/0272989X12458725","article-title":"Derivation of background mortality by smoking and obesity in cancer simulation models.","volume":"33","author":"Wang","year":"2013","journal-title":"Med Decis Making"},{"issue":"6","key":"zoi230843r18","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.","volume":"36","author":"Astrup","year":"2012","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"zoi230843r19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"issue":"9774","key":"zoi230843r20","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"issue":"11","key":"zoi230843r21","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi230843r22","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"14","key":"zoi230843r23","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1001\/jama.289.14.1813","article-title":"Health-related quality of life of severely obese children and adolescents.","volume":"289","author":"Schwimmer","year":"2003","journal-title":"JAMA"},{"issue":"2","key":"zoi230843r24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.248","article-title":"Cost-effectiveness of adolescent bariatric surgery.","volume":"7","author":"Bairdain","year":"2015","journal-title":"Cureus"},{"issue":"7","key":"zoi230843r25","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s11136-007-9226-0","article-title":"Utilities and disutilities for type 2 diabetes treatment-related attributes.","volume":"16","author":"Matza","year":"2007","journal-title":"Qual Life Res"},{"issue":"12","key":"zoi230843r26","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1097\/MLR.0000000000000581","article-title":"Measuring health-related quality of life in teens with and without depression.","volume":"54","author":"Lynch","year":"2016","journal-title":"Med Care"},{"issue":"8","key":"zoi230843r27","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMsa1616035","article-title":"Cost-effectiveness of intensive versus standard blood-pressure control.","volume":"377","author":"Bress","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi230843r28","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/jrh.2009.25.issue-3","article-title":"Comparison of program costs for parent-only and family-based interventions for pediatric obesity in medically underserved rural settings.","volume":"25","author":"Janicke","year":"2009","journal-title":"J Rural Health"},{"issue":"3","key":"zoi230843r29","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-2755","article-title":"Cost-effectiveness of family-based obesity treatment.","volume":"140","author":"Quattrin","year":"2017","journal-title":"Pediatrics"},{"issue":"3","key":"zoi230843r34","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S1553-7250(12)38016-1","article-title":"The costs of adverse drug events in community hospitals.","volume":"38","author":"Hug","year":"2012","journal-title":"Jt Comm J Qual Patient Saf"},{"issue":"5","key":"zoi230843r35","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/hec.v29.5","article-title":"The medical care costs of obesity and severe obesity in youth: an instrumental variables approach.","volume":"29","author":"Biener","year":"2020","journal-title":"Health Econ"},{"key":"zoi230843r36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide.","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"zoi230843r37","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.","volume":"38","author":"van Can","year":"2014","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"zoi230843r38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1506699","article-title":"Weight loss and health status 3 years after bariatric surgery in adolescents.","volume":"374","author":"Inge","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi230843r41","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/sj.ijo.0801838","article-title":"Cost-effectiveness of group and mixed family-based treatment for childhood obesity.","volume":"25","author":"Goldfield","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"7","key":"zoi230843r42","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40273-014-0182-6","article-title":"Cost-effectiveness analysis of Qsymia for weight loss.","volume":"33","author":"Finkelstein","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"zoi230843r44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/M20-1392","article-title":"A Health opportunity cost threshold for cost-effectiveness analysis in the United States.","volume":"174","author":"Vanness","year":"2021","journal-title":"Ann Intern Med"},{"issue":"12","key":"zoi230843r45","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/josh.2008.78.issue-12","article-title":"Cost-effectiveness of a school-based obesity prevention program.","volume":"78","author":"Wang","year":"2008","journal-title":"J Sch Health"},{"issue":"3","key":"zoi230843r46","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.acap.2015.07.009","article-title":"Cost and cost-effectiveness of Students for Nutrition and Exercise (SNAX).","volume":"16","author":"Ladapo","year":"2016","journal-title":"Acad Pediatr"},{"issue":"1","key":"zoi230843r47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.amepre.2015.03.032","article-title":"Cost effectiveness of childhood obesity interventions: evidence and methods for CHOICES.","volume":"49","author":"Gortmaker","year":"2015","journal-title":"Am J Prev Med"},{"issue":"2","key":"zoi230843r48","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamasurg.2016.3640","article-title":"Cost-effectiveness of bariatric surgery in adolescents with obesity.","volume":"152","author":"Klebanoff","year":"2017","journal-title":"JAMA Surg"},{"issue":"9","key":"zoi230843r49","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/13696998.2018.1468334","article-title":"A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States.","volume":"21","author":"Nuijten","year":"2018","journal-title":"J Med Econ"},{"issue":"7","key":"zoi230843r51","doi-asserted-by":"publisher","first-page":"740","DOI":"10.18553\/jmcp.2022.28.7.740","article-title":"Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States.","volume":"28","author":"Kim","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"zoi230843r52","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.numecd.2023.03.012","article-title":"Cost-effectiveness analysis of five anti-obesity medications from a US payer\u2019s perspective.","volume":"33","author":"G\u00f3mez Lumbreras","year":"2023","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"zoi230843r53","doi-asserted-by":"publisher","DOI":"10.1111\/cob.2019.9.issue-2","article-title":"Incremental cost-effectiveness of evidence-based non-surgical weight loss strategies.","volume":"9","author":"Finkelstein","year":"2019","journal-title":"Clin Obes"},{"issue":"6","key":"zoi230843r54","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-3034","article-title":"Stigma experienced by children and adolescents with obesity.","volume":"140","author":"Pont","year":"2017","journal-title":"Pediatrics"},{"issue":"12","key":"zoi230843r55","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1002\/oby.v30.12","article-title":"Addressing insurance-related barriers to novel antiobesity medications: lessons to be learned from bariatric surgery.","volume":"30","author":"Gasoyan","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"zoi230843r56","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ijo.2017.287","article-title":"US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity.","volume":"42","author":"Gomez","year":"2018","journal-title":"Int J Obes (Lond)"},{"key":"zoi230843r57","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.diabres.2018.07.017","article-title":"Persistence of newer anti-obesity medications in a real-world setting.","volume":"143","author":"Ganguly","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"zoi230843r30","unstructured":"Centers for Medicare & Medicaid Services. NADAC (National Average Drug Acquisition Cost) 2022. Accessed November 15, 2022. https:\/\/data.medicaid.gov\/dataset\/dfa2ab14-06c2-457a-9e36-5cb6d80f8d93"},{"key":"zoi230843r31","unstructured":"Merative. Micromedex Red Book (electronic version). Accessed November 7, 2022. https:\/\/www.micromedexsolutions.com\/"},{"key":"zoi230843r32","unstructured":"US Department of Veterans Affairs. Office of Procurement, Acquisitions and Logistics (OPAL): pharmaceutical prices. Accessed November 15, 2022. https:\/\/www.va.gov\/opal\/nac\/fss\/pharmPrices.asp"},{"key":"zoi230843r33","unstructured":"Centers for Medicare & Medicaid Services. Preventive Medicine office visit costs 2022. Accessed February 21, 2023. https:\/\/data.cms.gov\/provider-data\/dataset\/0330-b6e0"},{"key":"zoi230843r39","unstructured":"Centers for Disease Control and Prevention. CDC extended BMI-for-age growth charts. Accessed February 17, 2023. https:\/\/www.cdc.gov\/growthcharts\/extended-bmi.htm"},{"key":"zoi230843r40","unstructured":"Bureau of Labor Statistics. Economic News Release\u2014Table B-3: average hourly and weekly earnings of all employees on private nonfarm payrolls by industry sector, seasonally adjusted. Accessed June 20, 2020. https:\/\/www.bls.gov\/news.release\/empsit.t19.htm"},{"key":"zoi230843r43","unstructured":"Bureau of Economic Analysis. Price indexes for personal consumption expenditures by type of product, Table 2.4.4U. Accessed April 8, 2022. https:\/\/apps.bea.gov\/iTable\/?reqid=19&step=3&isuri=1&nipa_table_list=2017&categories=underlying"},{"key":"zoi230843r50","unstructured":"Institute For Clinical and Economic Review. Obesity management. Accessed July 5, 2023. https:\/\/icer.org\/assessment\/obesity-management-2022\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2808942\/lim_2023_oi_230843_1692815134.93754.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T15:57:59Z","timestamp":1693497479000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2808942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.29178","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]}}}